熱門資訊> 正文

Ionis获得额外的Tryngolza适应症

2026-06-25 04:18

The US FDA has approved an indicational indication for Ionis Pharmaceuticals' (IONS) Tryngolza (olezarsen) to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia.
The therapy is now the first available for the indication.
Tryngolza was initially approved in 2024 to cut triglycerides in adults with familial chylomicronemia syndrome.

More on Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc. (IONS) Presents at National Lipid Association (NLA) 2026 Scientific Sessions - Slideshow
Ionis Pharmaceuticals, Inc. (IONS) Presents at Endocrine Society's Annual Meeting (ENDO 2026) - Slideshow
Ionis Pharmaceuticals, Inc. (IONS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
GSK, Ionis mark late-stage trial win for chronic hepatitis B therapy
Ionis, Alnylam, BioMarin up as Citi starts at Buy on catalyst and growth outlook

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。